Will its acquisitions pay off for investors? In recent years, Amgen has been using acquisitions as a way to bolster its competitive position. And that's the big unknown for investors going forward ...

Swiss drugmaker Sandoz launched its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira biosimilar to hit the U.S. market, priced at a 5% and 55% ...

Amgen (AMGN) ended the recent trading session at $270, demonstrating a +1.33% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.74%.

Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024 ...

As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...

Amgen, with its obesity candidate MariTide and other promising treatments in its pipeline, could potentially surpass Eli Lilly in the obesity market. Amgen's stock is undervalued compared to Eli ...

Amgen has been busy with a couple of multi-billion dollar acquisitions over the past few years. While they should create growth opportunities, the drugmaker has also taken on quite a bit of debt.

April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due ... with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira ...

(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales ... its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita ...